Report cover image

Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review

Publisher GlobalData
Published Jul 17, 2023
Length 32 Pages
SKU # GBDT18092249

Description

Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer, and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Bristol Myers Squibb, Genmab, GSK, MD Anderson for the advancement of drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Mar 21,2023: Immatics Announces Full Year 2022 Financial Results and Corporate Update
Nov 17,2022: Immatics Announces Third Quarter 2022 Financial Results and Business Update
Jun 02,2022: Immatics Announces First Quarter 2022 Financial Results and Business Update
Mar 23,2022: Immatics Announces Full Year 2021 Financial Results and Corporate Update

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.

Table of Contents

32 Pages
Section 1 - About the Company
Immatics Biotechnologies GmbH - Key Facts
Immatics Biotechnologies GmbH - Key Employees
Immatics Biotechnologies GmbH - Key Employee Biographies
Immatics Biotechnologies GmbH - Major Products and Services
Immatics Biotechnologies GmbH - History
Immatics Biotechnologies GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Immatics Biotechnologies GmbH - Business Description
Immatics Biotechnologies GmbH - SWOT Analysis
SWOT Analysis - Overview
Immatics Biotechnologies GmbH - Strengths
Immatics Biotechnologies GmbH - Weaknesses
Immatics Biotechnologies GmbH - Opportunities
Immatics Biotechnologies GmbH - Threats
Immatics Biotechnologies GmbH - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Immatics Biotechnologies GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 21, 2023: Immatics Announces Full Year 2022 Financial Results and Corporate Update
Nov 17, 2022: Immatics Announces Third Quarter 2022 Financial Results and Business Update
Jun 02, 2022: Immatics Announces First Quarter 2022 Financial Results and Business Update
Mar 23, 2022: Immatics Announces Full Year 2021 Financial Results and Corporate Update
Jan 27, 2022: Immatics Announces Changes to its Board of Directors
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Immatics Biotechnologies GmbH, Key Facts
Immatics Biotechnologies GmbH, Key Employees
Immatics Biotechnologies GmbH, Key Employee Biographies
Immatics Biotechnologies GmbH, Major Products and Services
Immatics Biotechnologies GmbH, History
Immatics Biotechnologies GmbH, Other Locations
Immatics Biotechnologies GmbH, Key Competitors
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Immatics Biotechnologies GmbH, Recent Deals Summary
List of Figures
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us